Source-grounded facts extracted from INVO Fertility, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
INVO Fertility, Inc. reported fourth quarter ended December 31, 2022 results: revenue $278,142.
“Q4 2022 Financial Highlights (all metrics compared to Q4 2021 unless otherwise noted) ● Revenue was $278,142, compared to $12,532 (excluding license revenue), and was up 18% sequentially compared to the third quarter of 2022.”
Jeffrey Segal resigned as director at INVO Fertility, Inc..
“On March 31, 2023, Jeffrey Segal MD submitted his resignation as a director of INVO Bioscience, Inc. (the “Company”).”
INVO Fertility, Inc. reported preliminary financial results for fourth quarter and year ended December 31, 2022.
“On March 30, 2023, INVO Bioscience, Inc. (the "Company") issued a press release announcing preliminary financial results for the fourth quarter and the year ended December 31, 2022.”
INVO Fertility, Inc. entered into Placement Agency Agreement with Maxim Group LLC (effective 2023-03-23).
“Also in connection with the offering, on March 23, 2023, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with Maxim Group LLC”
INVO Fertility, Inc. entered into Purchase Agreement with certain institutional investors (effective 2023-03-23).
“On March 23, 2023, INVO Bioscience, Inc., a Nevada corporation (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors”
INVO Fertility, Inc. incurred convertible notes of $135,000 at ten percent (10%) per annum maturing December 31, 2023.
“the Company entered into definitive securities purchase agreements (the “Purchase Agreements”) with accredited investors for their purchase of (i) unsecured convertible notes of the Company in the aggregate original principal amount of $135,000 (the “Notes”) with a fixed conversion price of $0.60”
INVO Fertility, Inc. entered into Purchase Agreements with accredited investors valued at $135,000 (effective 2023-03-17).
“On March 17, 2023, the Company entered into definitive securities purchase agreements (the “Purchase Agreements”) with accredited investors for their purchase of (i) unsecured convertible notes of the Company in the aggregate original principal amount of $135,000 (the “Notes”)”
INVO Fertility, Inc. entered into Membership Interest Purchase Agreement with FLOW, IVF Science, LLC, owned by Wael Megid, Ph.D., and Dr. Elizabeth Pritts as trustee for the Elizabeth Pritts Revocable List Trust (effective 2023-03-16).
“On March 16, 2023, Buyer entered into a Membership Interest Purchase Agreement (the “MIPA”) with FLOW, IVF Science, LLC, a Wisconsin limited liability company (“IVF Science”), owned by Wael Megid, Ph.D. (“Dr. Megid”), and Dr. Elizabeth Pritts as trustee for the Elizabeth Pritts Revocable List Trust, a Trust created under the laws of the State of Wisconsin (each, a “Selling Member” and collectively, the “Selling Members”).”
INVO Fertility, Inc. entered into Asset Purchase Agreement with WFRSA and The Elizabeth Pritts Revocable Living Trust (effective 2023-03-16).
“On March 16, 2023, Buyer entered into an Asset Purchase Agreement (the “APA”) with WFRSA and The Elizabeth Pritts Revocable Living Trust (the “Seller,” together with the WFRSA, the “Seller Parties”) pursuant to which Buyer agreed to acquire the Purchased Assets (as defined in the APA) related to WFRSA’s business.”
INVO Fertility, Inc. entered into Membership Interest Purchase Agreement with FLOW, IVF Science, LLC, and Dr. Elizabeth Pritts as trustee for the Elizabeth Pritts Revocable List Trust (effective 2023-03-16).
“On March 16, 2023, Buyer entered into a Membership Interest Purchase Agreement (the “MIPA”) with FLOW, IVF Science, LLC, a Wisconsin limited liability company (“IVF Science”), owned by Wael Megid, Ph.D. (“Dr. Megid”), and Dr. Elizabeth Pritts as trustee for the Elizabeth Pritts Revocable List Trust, a Trust created under the laws of the State of Wisconsin (each, a “Selling Member” and collectively, the “Selling Members”).”
INVO Fertility, Inc. entered into Asset Purchase Agreement with WFRSA and The Elizabeth Pritts Revocable Living Trust (effective 2023-03-16).
“On March 16, 2023, Buyer entered into an Asset Purchase Agreement (the “APA”) with WFRSA and The Elizabeth Pritts Revocable Living Trust (the “Seller,” together with the WFRSA, the “Seller Parties”) pursuant to which Buyer agreed to acquire the Purchased Assets (as defined in the APA) related to WFRSA’s business.”
INVO Fertility, Inc. incurred convertible notes of $200,000 with Firstfire Global Opportunities Fund, LLC at 8% per annum maturing February 17, 2024.
“On February 17 2023 (the “Closing”), INVO Bioscience, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with Firstfire Global Opportunities Fund, LLC, an accredited investor (the “Buyer”) for the purchase of (i) a convertible debenture of the Company (the “Debenture”) in the aggregate original principal amount of $200,000”
INVO Fertility, Inc. entered into Purchase Agreement with Firstfire Global Opportunities Fund, LLC valued at $200,000 (effective 2023-02-17).
“On February 17 2023 (the “Closing”), INVO Bioscience, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with Firstfire Global Opportunities Fund, LLC, an accredited investor (the “Buyer”) for the purchase of (i) a convertible debenture of the Company (the “Debenture”) in the aggregate original principal amount of $200,000”
INVO Fertility, Inc. incurred convertible notes of $300,000 with Peak One Opportunity Fund, LP at eight percent (8%) per annum maturing February 3, 2024.
“On February 3, 2023 (the “Closing”), INVO Bioscience, Inc. (the “Company”) entered into securities purchase agreement (“Purchase Agreement”) with Peak One Opportunity Fund, LP, an accredited investor (the “Buyer”) for the purchase of (i) a convertible debenture of the Company (the “Debenture”) in the aggregate original principal amount of $300,000”
INVO Fertility, Inc. entered into Purchase Agreement with Peak One Opportunity Fund, LP (effective 2023-02-03).
“On February 3, 2023 (the “Closing”), INVO Bioscience, Inc. (the “Company”) entered into securities purchase agreement (“Purchase Agreement”) with Peak One Opportunity Fund, LP, an accredited investor (the “Buyer”) for the purchase of (i) a convertible debenture of the Company (the “Debenture”) in the aggregate original principal amount of $300,000 (the “Debenture”) for a purchase price of $270,000”
INVO Fertility, Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)).
“January 18, 2023 letter from Nasdaq granting an extension of time to regain compliance with Nasdaq Listing Rule 5550(b) until May 22, 2023. Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On November 23, 2022, INVO Bioscience, Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on”
INVO Fertility, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“(the “Stockholders’ Equity Requirement). In the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, the Company reported stockholders’ equity of $1,287,224, which is below the Stockholders’ Equity Requirement for continued listing. Additionally, as of the date of the Notice, the Company did not meet either of the alternative Nasdaq”
INVO Fertility, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“January 11, 2023, INVO Bioscience Inc. (the “Company”) received a letter from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) listing qualifications group indicating that, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing under Nasdaq Listing Rule 5550(a)(2). The notice has no immediate effect on the listing of the Company’s common stock, and its common stock will continue to trade on T”
INVO Fertility, Inc. amended loan of $400,000 with JAG Multi Investments LLC maturing March 31, 2023.
“the date on which JAG can demand payment of principal, fees and any interest under those certain demand promissory previously issued to JAG by the Company for a total of $400,000, of which JAG may demand payment of $350,000 as of the date hereof, be extended to March 31, 2023”
INVO Fertility, Inc. incurred loan of $100,000 with JAG Multi Investments LLC at 10% annual interest.
“with JAG Multi Investments LLC (“JAG”), a related party to Andrea Goren, our CFO, who is a beneficiary of JAG but does”
INVO Fertility, Inc. entered into Purchase Agreements with accredited investors valued at $275,000 (effective 2023-01-04).
“the Company entered into definitive securities purchase agreements (the “Purchase Agreements”) with accredited investors for their purchase of (i) unsecured convertible notes of the Company in the aggregate original principal amount of $275,000”
INVO Fertility, Inc. entered into Distribution Agreement with Ming Mei Technology Co. Ltd (effective 2023-01-03).
“On January 3, 2023, we entered into a Distribution Agreement with Ming Mei Technology Co. Ltd (“Distributor”) to distribute the INVOcell system to Taiwan (ROC) under which Distributor was appointed as the exclusive distributor in Taiwan (ROC).”
INVO Fertility, Inc. incurred loan of $100,000 at 10% annual interest.
“On December 13, 2022, INVO Bioscience, Inc. (the “Company”) received $100,000 through the issuance of demand promissory notes of which (1) $25,000 was received from our chief executive officer, Steven Shum, (2) $25,000 was received from an entity controlled by our chief financial officer, Andrea Goren, and (3) $50,000 was received from JAG Multi Investments LLC (“JAG”), a related party to Mr. Goren, who is a beneficiary of JAG but does not have any control over JAG’s investment decisions with respect to the Company.”
INVO Fertility, Inc. incurred loan of $150,000 with Steven Shum and entity controlled by Andrea Goren at 10% annual interest.
“From November 29, 2022 through December 2, 2022, INVO Bioscience, Inc. (the “Company”) received $150,000 through the issuance of demand promissory notes of which (1) $75,000 was received from our Chief Executive Officer, Steven Shum ($60,000 on November 29, 2022 and $15,000 on December 2, 2022) and (2) $75,000 was received from an entity controlled by our Chief Financial Officer, Andrea Goren (on November 29, 2022). If paid prior to January 31, 2023, the demand promissory notes are interest free until January 31, 2023. For any amount that remains outstanding past January 31, 2023, 10% annual interest would accrue from the date of issuance.”
INVO Fertility, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“(the “Stockholders’ Equity Requirement). In the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, the Company reported stockholders’ equity of $1,287,224, which is below the Stockholders’ Equity Requirement for continued listing. Additionally, as of the date of the Notice, the Company did not meet either of the alternative Nasdaq”
INVO Fertility, Inc. reported the third quarter ended September 30, 2022 results: revenue $235,321.
“Revenue for the three months ended September 30, 2022, was $235,321 compared to $218,874 for the three months ended September 30, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.